A Phase 2/3 interventional study of ABT-493 and ABT-530 in Chronic Hepatitis C and Hepatitis C Virus, sponsored by AbbVie. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-30.
Sponsored by AbbVie · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Hepatitis C, Chronic by AbbVie — none open to participants now, none under way, none of them phase 3. Hepatitis C, Chronic · AbbVie.
Among the 83 studies in Hepatitis C, Chronic by AbbVie, this one is the 3rd largest by enrollment of the 58 interventional ones that give a count, is one of 11 that started in 2014, is one of 5 in phase 2/3, and was the 25th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 83 studies in Hepatitis C, Chronic by AbbVie is open now. The open studies under Hepatitis C, Chronic, anywhere →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 18 · Phase 3 45
First in 2009; this study’s year is marked. 11 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 694 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 144 across the 58 interventional studies, 244 across the 25 observational. Of the 82 that completed or were terminated, 74 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 83 studies in Hepatitis C, Chronic by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this phase 2/3, open-label, multipart, multicenter study was to evaluate the efficacy, and safety of co-administration of ABT-493 and ABT-530 with and without ribavirin (RBV) in chronic HCV genotype 2 (GT2-), genotype 3 (GT3-), genotype 4 (GT4), genotype 5 (GT5-), or genotype 6 (GT6-) infected participants with or without cirrhosis.
The study consisted of four independent parts with treatment and post-treatment periods of enrollment. Parts 1 and 2 were the supportive/ exploratory parts (phase 2) of the study and part 3 and 4 were the confirmatory/ registrational parts (phase 3) of the study. In parts 1 and 2 of the study, ABT-493 and ABT-530 were co-administered as separate tablets. However, in parts 3 and 4 of the study, the ABT-493/ABT-530 co-formulated tablets were administered.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 2 (GT2) -infected treatment naïve and treatment experienced participants without cirrhosis.
Drug: ABT-493 · Drug: ABT-530
ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
Drug: ABT-493 · Drug: ABT-530
ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided twice daily (BID) for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
Drug: ABT-493 · Drug: ABT-530 · Drug: ribavirin (RBV)
ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 3 (GT3) -infected treatment naïve and treatment experienced participants without cirrhosis.
Drug: ABT-493 · Drug: ABT-530
ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
Drug: ABT-493 · Drug: ABT-530
ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided BID for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
Drug: ABT-493 · Drug: ABT-530 · Drug: ribavirin (RBV)
ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
Drug: ABT-493 · Drug: ABT-530
ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
Drug: ABT-493 · Drug: ABT-530
ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
Drug: ABT-493 · Drug: ABT-530
ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
Drug: ABT-493 · Drug: ABT-530
ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
Drug: ABT-493 · Drug: ABT-530
ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
Drug: ABT-493 · Drug: ABT-530
ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.
Drug: ABT-493 · Drug: ABT-530
ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD and ribavirin (RBV) (800 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.
Drug: ABT-493 · Drug: ABT-530 · Drug: ribavirin (RBV)
ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis and for 16 weeks in HCV GT3 -infected treatment-experienced participants with compensated cirrhosis.
Drug: ABT-493 · Drug: ABT-530
ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and RBV (800 mg) QD for 12 weeks in HCV GT3-infected treatment naïve and treatment-experienced participants with compensated cirrhosis.
Drug: ABT-493 · Drug: ABT-530 · Drug: ribavirin (RBV)
ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment naïve participants with cirrhosis.
Drug: ABT-493/ABT-530
ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
Drug: ABT-493/ABT-530
ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
Drug: ABT-493/ABT-530
ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants with cirrhosis.
Drug: ABT-493/ABT-530
ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT2 infected treatment naïve and treatment experienced participants without cirrhosis.
Drug: ABT-493/ABT-530
ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT4-6 infected treatment naïve and treatment experienced participants without cirrhosis.
Drug: ABT-493/ABT-530
Tablet
Also known as: glecaprevir
Tablet
Also known as: pibrentasvir
Tablet
Drug page: Glecaprevir and pibrentasvir
Tablet; ABT-493 co-formulated ABT-530
Also known as: ABT-493 also known as glecaprevir, ABT-530 also known as pibrentasvir, MAVYRET
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug.
Time frame: 12 weeks after the last actual dose of study drug
Percentage of Genotype 2 (GT2) Direct-acting Antiviral Agents (DAA)-Naive Participants (in Part 4, Arm S1) With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) as Compared to Historical Control
SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug.
Time frame: 12 weeks after the last actual dose of study drug
Percentage of Participants With Sustained Virologic Response 4 Weeks Post-treatment (SVR4)
SVR4 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 4 weeks after the last dose of study drug.
Time frame: 4 weeks after the last actual dose of study drug
Percentage of Participants With On-treatment Virologic Failure
On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment; confirmed increase of \> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline in HCV RNA during treatment; or HCV RNA ≥ LLOQ at end of treatment with at least 6 weeks of treatment.
Time frame: Up to end of treatment (treatment week 8, 12 or 16 depending on arm) or premature discontinuation from treatment
Percentage of Participants With Post-treatment Relapse
Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels \< LLOQ at the end of treatment, excluding reinfection.
Time frame: From the end of treatment through 12 weeks after the last dose of study drug
Enrollment into arms H, I, K, M and N was not opened by AbbVie.
| Milestone | Arm A | Arm B | Arm C | Arm D | Arm E | Arm F | Arm G | Arm H | Arm I | Arm J | Arm K | Arm L | Arm M | Arm N | Arm O | Arm P | Arm Q1 | Arm Q2 | Arm R1 | Arm R2 | Arm S1 | Arm S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 25 | 24 | 25 | 30 | 31 | 31 | 30 | 0 | 0 | 55 | 0 | 53 | 0 | 0 | 28 | 27 | 40 | 22 | 22 | 48 | 145 | 58 |
| Completed | 23 | 23 | 24 | 29 | 30 | 31 | 27 | 0 | 0 | 53 | 0 | 50 | 0 | 0 | 27 | 26 | 37 | 21 | 22 | 47 | 143 | 55 |
| Not completed | 2 | 1 | 1 | 1 | 1 | 0 | 3 | 0 | 0 | 2 | 0 | 3 | 0 | 0 | 1 | 1 | 3 | 1 | 0 | 1 | 2 | 3 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 1 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 1 | 2 |
| Withdrew: Enrolled into a re-treatment study | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized but did'nt receive study drug | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug.
| percentage of participants | Arm A | Arm B | Arm C | Arm D | Arm E | Arm F | Arm G | Arm J | Arm L | Arm O | Arm P | Arm Q1 | Arm Q2 | Arm R1 | Arm R2 | Arm S1 | Arm S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) | 96.0 (80.5 to 99.3) | 100.0 (86.2 to 100.0) | 100.0 (86.7 to 100.0) | 93.3 (78.7 to 98.2) | 93.3 (78.7 to 98.2) | 93.5 (79.3 to 98.2) | 83.3 (66.4 to 92.7) | 98.1 (90.2 to 99.7) | 94.3 (84.6 to 98.1) | 96.4 (82.3 to 99.4) | 100.0 (87.5 to 100.0) | 97.5 (87.1 to 99.6) | 90.9 (72.2 to 97.5) | 95.5 (78.2 to 99.2) | 95.7 (85.8 to 98.8) | 97.9 (94.1 to 99.3) | 93.1 (83.6 to 97.3) |
SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug.
| percentage of participants | Arm S1 |
|---|---|
| Percentage of Genotype 2 (GT2) Direct-acting Antiviral Agents (DAA)-Naive Participants (in Part 4, Arm S1) With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) as Compared to Historical Control | 98.5 (96.5 to 100.0) |
SVR4 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 4 weeks after the last dose of study drug.
| percentage of participants | Arm A | Arm B | Arm C | Arm D | Arm E | Arm F | Arm G | Arm J | Arm L | Arm O | Arm P | Arm Q1 | Arm Q2 | Arm R1 | Arm R2 | Arm S1 | Arm S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Sustained Virologic Response 4 Weeks Post-treatment (SVR4) | 96.0 (80.5 to 99.3) | 100.0 (86.2 to 100.0) | 100.0 (86.7 to 100.0) | 93.3 (78.7 to 98.2) | 93.3 (78.7 to 98.2) | 93.5 (79.3 to 98.2) | 93.3 (78.7 to 98.2) | 98.1 (90.2 to 99.7) | 96.2 (87.2 to 99.0) | 96.4 (82.3 to 99.4) | 100.0 (87.5 to 100.0) | 97.5 (87.1 to 99.6) | 95.5 (78.2 to 99.2) | 95.5 (78.2 to 99.2) | 95.7 (85.8 to 98.8) | 97.9 (94.1 to 99.3) | 98.3 (90.9 to 99.7) |
On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment; confirmed increase of \> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline in HCV RNA during treatment; or HCV RNA ≥ LLOQ at end of treatment with at least 6 weeks of treatment.
| percentage of participants | Arm A | Arm B | Arm C | Arm D | Arm E | Arm F | Arm G | Arm J | Arm L | Arm O | Arm P | Arm Q1 | Arm Q2 | Arm R1 | Arm R2 | Arm S1 | Arm S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With On-treatment Virologic Failure | 0 (0.0 to 13.3) | 0 (0.0 to 13.8) | 0 (0.0 to 13.3) | 0 (0.0 to 11.4) | 0 (0.0 to 11.4) | 3.2 (0.6 to 16.2) | 3.3 (0.6 to 16.7) | 0 (0.0 to 6.6) | 1.9 (0.3 to 9.9) | 0 (0.0 to 12.1) | 0 (0.0 to 12.5) | 0 (0.0 to 8.8) | 0 (0.0 to 14.9) | 0 (0.0 to 14.9) | 2.1 (0.4 to 11.1) | 0 (0.0 to 2.6) | 0 (0.0 to 6.2) |
Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels \< LLOQ at the end of treatment, excluding reinfection.
| percentage of participants | Arm A | Arm B | Arm C | Arm D | Arm E | Arm F | Arm G | Arm J | Arm L | Arm O | Arm P | Arm Q1 | Arm Q2 | Arm R1 | Arm R2 | Arm S1 | Arm S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Post-treatment Relapse | 0.0 (0.0 to 13.8) | 0.0 (0.0 to 13.8) | 0.0 (0.0 to 13.3) | 3.4 (0.6 to 17.2) | 6.7 (1.8 to 21.3) | 0.0 (0.0 to 12.1) | 7.1 (2.0 to 22.6) | 0.0 (0.0 to 6.8) | 2.0 (0.3 to 10.3) | 3.6 (0.6 to 17.7) | 0.0 (0.0 to 12.5) | 0 (0.0 to 9.0) | 9.1 (2.5 to 27.8) | 4.5 (0.8 to 21.8) | 2.2 (0.4 to 11.3) | 1.4 (0.4 to 4.9) | 0 (0.0 to 6.3) |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the time of study drug administration until 30 days after the last dose of study drug (up to 20 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ARM A | 1/25 (4%) | 0/25 (0%) | 12/25 (48%) |
| ARM B | 0/24 (0%) | 0/24 (0%) | 11/24 (45.8%) |
| ARM C | 0/25 (0%) | 1/25 (4%) | 22/25 (88%) |
| ARM D | 0/30 (0%) | 0/30 (0%) | 19/30 (63.3%) |
| ARM E | 0/30 (0%) | 0/30 (0%) | 20/30 (66.7%) |
| ARM F | 0/31 (0%) | 2/31 (6.5%) | 23/31 (74.2%) |
| ARM G | 0/30 (0%) | 0/30 (0%) | 18/30 (60%) |
| ARM J | 0/54 (0%) | 1/54 (1.9%) | 26/54 (48.1%) |
| ARM L | 0/53 (0%) | 1/53 (1.9%) | 40/53 (75.5%) |
| ARM O | 0/28 (0%) | 2/28 (7.1%) | 20/28 (71.4%) |
| ARM P | 1/27 (3.7%) | 2/27 (7.4%) | 21/27 (77.8%) |
| ARM Q1 | 0/40 (0%) | 1/40 (2.5%) | 30/40 (75%) |
| ARM Q2 | 0/22 (0%) | 1/22 (4.5%) | 12/22 (54.5%) |
| ARM R1 | 0/22 (0%) | 1/22 (4.5%) | 13/22 (59.1%) |
| ARM R2 | 0/47 (0%) | 3/47 (6.4%) | 31/47 (66%) |
| ARM S1 | 1/145 (0.7%) | 1/145 (0.7%) | 78/145 (53.8%) |
| ARM S2 | 0/58 (0%) | 1/58 (1.7%) | 32/58 (55.2%) |
| Event | ARM A | ARM B | ARM C | ARM D | ARM E | ARM F | ARM G | ARM J | ARM L | ARM O | ARM P | ARM Q1 | ARM Q2 | ARM R1 | ARM R2 | ARM S1 | ARM S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SchizophreniaPsychiatric disorders | 0/25 | 0/24 | 0/25 | 0/30 | 0/30 | 0/31 | 0/30 | 0/54 | 0/53 | 0/28 | 0/27 | 0/40 | 1/22 | 0/22 | 0/47 | 0/145 | 0/58 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/25 | 0/24 | 0/25 | 0/30 | 0/30 | 0/31 | 0/30 | 0/54 | 0/53 | 0/28 | 0/27 | 0/40 | 0/22 | 1/22 | 0/47 | 0/145 | 0/58 |
| Atrial fibrillationCardiac disorders | 0/25 | 0/24 | 1/25 | 0/30 | 0/30 | 0/31 | 0/30 | 0/54 | 0/53 | 0/28 | 0/27 | 0/40 | 0/22 | 0/22 | 0/47 | 0/145 | 0/58 |
| AnaemiaBlood and lymphatic system disorders | 0/25 | 0/24 | 0/25 | 0/30 | 0/30 | 0/31 | 0/30 | 0/54 | 0/53 | 0/28 | 1/27 | 0/40 | 0/22 | 0/22 | 0/47 | 0/145 | 0/58 |
| Delusional disorder, unspecified typePsychiatric disorders | 0/25 | 0/24 | 0/25 | 0/30 | 0/30 | 0/31 | 0/30 | 0/54 | 0/53 | 0/28 | 1/27 | 0/40 | 0/22 | 0/22 | 0/47 | 0/145 | 0/58 |
| Tibia fractureInjury, poisoning and procedural complications | 0/25 | 0/24 | 0/25 | 0/30 | 0/30 | 0/31 | 0/30 | 0/54 | 0/53 | 1/28 | 0/27 | 0/40 | 0/22 | 0/22 | 0/47 | 0/145 | 0/58 |
| Hepatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/25 | 0/24 | 0/25 | 0/30 | 0/30 | 0/31 | 0/30 | 0/54 | 0/53 | 1/28 | 0/27 | 0/40 | 0/22 | 0/22 | 0/47 | 0/145 | 0/58 |
| PneumoniaInfections and infestations | 0/25 | 0/24 | 0/25 | 0/30 | 0/30 | 1/31 | 0/30 | 0/54 | 0/53 | 0/28 | 0/27 | 0/40 | 0/22 | 0/22 | 0/47 | 0/145 | 0/58 |
| B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/25 | 0/24 | 0/25 | 0/30 | 0/30 | 1/31 | 0/30 | 0/54 | 0/53 | 0/28 | 0/27 | 0/40 | 0/22 | 0/22 | 0/47 | 0/145 | 0/58 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/25 | 0/24 | 0/25 | 0/30 | 0/30 | 0/31 | 0/30 | 0/54 | 0/53 | 0/28 | 0/27 | 1/40 | 0/22 | 0/22 | 0/47 | 0/145 | 0/58 |
| Event | ARM A | ARM B | ARM C | ARM D | ARM E | ARM F | ARM G | ARM J | ARM L | ARM O | ARM P | ARM Q1 | ARM Q2 | ARM R1 | ARM R2 | ARM S1 | ARM S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 2/25 | 3/24 | 10/25 | 6/30 | 5/30 | 12/31 | 2/30 | 7/54 | 15/53 | 3/28 | 8/27 | 5/40 | 4/22 | 4/22 | 16/47 | 24/145 | 13/58 |
| NauseaGastrointestinal disorders | 3/25 | 1/24 | 8/25 | 2/30 | 6/30 | 11/31 | 0/30 | 5/54 | 4/53 | 3/28 | 7/27 | 4/40 | 2/22 | 2/22 | 5/47 | 18/145 | 5/58 |
| HeadacheNervous system disorders | 1/25 | 3/24 | 6/25 | 4/30 | 3/30 | 6/31 | 5/30 | 6/54 | 17/53 | 5/28 | 9/27 | 10/40 | 5/22 | 4/22 | 6/47 | 17/145 | 11/58 |
| DiarrhoeaGastrointestinal disorders | 4/25 | 1/24 | 6/25 | 2/30 | 1/30 | 2/31 | 2/30 | 4/54 | 8/53 | 6/28 | 1/27 | 4/40 | 1/22 | 2/22 | 1/47 | 4/145 | 2/58 |
| Upper respiratory tract infectionInfections and infestations | 1/25 | 1/24 | 5/25 | 4/30 | 1/30 | 1/31 | 1/30 | 1/54 | 4/53 | 5/28 | 2/27 | 3/40 | 1/22 | 0/22 | 2/47 | 10/145 | 3/58 |
| InsomniaPsychiatric disorders | 0/25 | 0/24 | 2/25 | 1/30 | 2/30 | 3/31 | 1/30 | 3/54 | 5/53 | 0/28 | 5/27 | 1/40 | 0/22 | 0/22 | 3/47 | 1/145 | 2/58 |
| Back painMusculoskeletal and connective tissue disorders | 1/25 | 0/24 | 0/25 | 1/30 | 1/30 | 0/31 | 2/30 | 3/54 | 1/53 | 0/28 | 3/27 | 4/40 | 0/22 | 4/22 | 0/47 | 6/145 | 2/58 |
| DizzinessNervous system disorders | 2/25 | 0/24 | 0/25 | 1/30 | 1/30 | 5/31 | 0/30 | 0/54 | 1/53 | 2/28 | 4/27 | 4/40 | 1/22 | 0/22 | 1/47 | 7/145 | 2/58 |
| SinusitisInfections and infestations | 1/25 | 0/24 | 4/25 | 1/30 | 2/30 | 1/31 | 0/30 | 0/54 | 1/53 | 1/28 | 1/27 | 0/40 | 0/22 | 0/22 | 0/47 | 3/145 | 0/58 |
| Haemoglobin decreasedInvestigations | 0/25 | 0/24 | 4/25 | 0/30 | 0/30 | 4/31 | 0/30 | 0/54 | 0/53 | 0/28 | 2/27 | 0/40 | 0/22 | 0/22 | 0/47 | 0/145 | 0/58 |
All participants who received atleast 1 dose of study drug (ITT population)
| Age, Customized(participants) | Arm A | Arm B | Arm C | Arm D | Arm E | Arm F | Arm G | Arm J | Arm L | Arm O | Arm P | Arm Q1 | Arm Q2 | Arm R1 | Arm R2 | Arm S1 | Arm S2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| < 65 years | 21 | 21 | 22 | 28 | 29 | 30 | 28 | 44 | 52 | 26 | 24 | 38 | 18 | 19 | 39 | 128 | 49 | 616 |
| >= 65 years | 4 | 3 | 3 | 2 | 1 | 1 | 2 | 10 | 1 | 2 | 3 | 2 | 4 | 3 | 8 | 17 | 9 | 75 |
| Sex: Female, Male(Participants) | Arm A | Arm B | Arm C | Arm D | Arm E | Arm F | Arm G | Arm J | Arm L | Arm O | Arm P | Arm Q1 | Arm Q2 | Arm R1 | Arm R2 | Arm S1 | Arm S2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 9 | 11 | 7 | 11 | 16 | 12 | 15 | 21 | 21 | 13 | 9 | 16 | 8 | 8 | 11 | 84 | 21 | 293 |
| Male | 16 | 13 | 18 | 19 | 14 | 19 | 15 | 33 | 32 | 15 | 18 | 24 | 14 | 14 | 36 | 61 | 37 | 398 |
| Ethnicity (NIH/OMB)(Participants) | Arm A | Arm B | Arm C | Arm D | Arm E | Arm F | Arm G | Arm J | Arm L | Arm O | Arm P | Arm Q1 | Arm Q2 | Arm R1 | Arm R2 | Arm S1 | Arm S2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 4 | 4 | 3 | 5 | 5 | 6 | 2 | 4 | 2 | 9 | 1 | 0 | 4 | 11 | 2 | 65 |
| Not Hispanic or Latino | 24 | 22 | 21 | 26 | 27 | 26 | 25 | 48 | 51 | 24 | 25 | 31 | 21 | 22 | 43 | 134 | 56 | 626 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No study locations are listed for this record.
The record gives a start of Sep 2014, a primary completion of Oct 2016 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2017, 11 months after primary completion. A results delay was requested in Feb 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Glecaprevir · Pibrentasvir · Ribavirin · Glecaprevir and pibrentasvir